Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of leniolisib 70 mg capsule versus tablet in healthy volunteers
NL-OMON49922Completed
- Sponsor
- Pharming Group
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of leniolisib in Activated PI3Kδ syndrome (APDS) (2 arms), sponsored by Pharming Group. Primary endpoint: Bioequivalence of leniolisib capsule versus tablet. Started Aug 2021; status: completed.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on NL-OMON49922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49922.